Skip to content
synovial sarcoma foundation
  • About
    • Mission
    • Initiatives
    • Affiliations
    • Leadership
    • Board of Directors
    • Medical Advisory Board
    • Careers
  • Resources
    • Synovial Sarcoma FAQ
    • Treatments
    • Clinical Trials & Therapies
    • Synovial Sarcoma Patient Survey
    • Synovial Sarcoma Tumor Board
    • Patient Stories
    • Patient Resources
    • Eddie’s Story
    • Video Resources
    • SSF Ambassador Program
  • Research Programs
    • Clinical Research
    • Tumor Glow
    • Synovial Sarcoma Registry
  • Latest News
Donate

Send us a note

Please fill out the form below and we will gladly respond as soon as possible.



    CHOP, Development, Dr. Theodore Laetsch, Research

    Synovial Sarcoma Foundation Celebrates Groundbreaking Achievement by Rachel Dr. Hurly

    June 3, 2025 joshs Comments Off on Synovial Sarcoma Foundation Celebrates Groundbreaking Achievement by Rachel Dr. Hurly
    A smiling woman with glasses holds an award plaque in front of a backdrop featuring “CONQUER CANCER,” “RESEARCH CONQUERS CANCER,” and Synovial Sarcoma Foundation logos from The ASCO Foundation.

    Dr. Hurly’s Innovative Work Aims at Improving Therapeutic Options for Patients with Synovial Sarcoma

    Philadelphia, PA — The Synovial Sarcoma Foundation is proud to announce a significant milestone: Dr. Rachel Hurly, a dedicated pediatric oncology fellow from the Children’s Hospital of Philadelphia (CHOP), has been honored with the prestigious American Society of Clinical Oncology (ASCO) Young Investigator Award. Dr. Hurly conducts her research under the mentorship of Dr. Ted Laetsch at the Haldor Laboratory at the University of Pennsylvania, with support from the Synovial Sarcoma Foundation.

    Dr. Hurly’s project focuses on the tumor microenvironment (TME) and its role in enabling or hindering the effectiveness of immunotherapy, specifically investigating the modulation of the TME through the inhibition of retinaldehyde dehydrogenase (RALDH). Early findings suggest that targeting RALDH could promote immune responses against the tumor and enhance the efficacy of existing immunotherapies.

    Chas Spence, Executive Director and Founder of the Synovial Sarcoma Foundation, stated, “Dr. Hurly’s research holds tremendous promise for advancing our understanding of how to manipulate the tumor microenvironment to make immunotherapies more effective for children with synovial sarcoma. Her dedication and innovative approach are truly inspiring.”

    Spence continued, “Our family’s journey with our son Callan’s diagnosis motivated us to become lifelong advocates for synovial sarcoma research. Dr. Hurly’s research and her strong foundation will help propel these efforts forward.”

    The Foundation acknowledges the significant importance of this research, which has the potential to revolutionize the treatment landscape for pediatric sarcoma. The project’s preliminary data highlights promising avenues for future therapeutic development, aiming to improve survival rates and quality of life for young patients.

    “This recognition not only underscores the significance of Dr. Hurly’s research but also emphasizes the vital role that collaborative efforts and dedicated funding play in tackling rare cancers,” added Spence. “We remain committed to supporting groundbreaking research that offers hope and new possibilities for children afflicted by synovial sarcoma and other pediatric cancers.”

    The Synovial Sarcoma Foundation extends its congratulations to Dr. Hurly and her team and remains steadfast in its mission to fund innovative research, foster collaboration, and improve outcomes for pediatric sarcoma patients worldwide.

    About the Synovial Sarcoma Foundation
    The Synovial Sarcoma Foundation is dedicated to funding research, supporting patients and families, and advancing the understanding of synovial sarcoma and related soft tissue sarcomas. Through collaborative efforts, the Foundation aims to accelerate discoveries that lead to more effective treatments and, ultimately, cures.

    • Cancer Research
    • Chase Spence
    • CHOP
    • Dr. Rachel Hurly
    • Dr. Ted Laetsch
    • Pediatric Oncology
    • Rare Cancer
    • Sarcoma
    • Synovial Sarcoma Foundation
    joshs

    Post navigation

    Previous
    Next

    Search

    Categories

    • Black Flag Racing (2)
    • Case Study (5)
    • Children (1)
    • CHOP (3)
    • Clinical Trial (4)
    • Development (12)
    • Dr. Theodore Laetsch (3)
    • Education (27)
    • Europe Expansion (1)
    • Healthcare (13)
    • Latest News (22)
    • Patient Story (1)
    • Programs (1)
    • Rare Cancer (7)
    • Rare Cancer Funding (2)
    • Research (21)
    • SSF Ambassador Program (1)
    • Synovial Sarcoma Conference (2)
    • Synovial Sarcoma Registry (7)
    • Teresa Belluco (1)
    • Tumor Board (2)

    Recent posts

    • A doctor in a white coat with a stethoscope around their neck holds a tablet device, standing in a medical setting with a patient lying on a bed in the background.
      Synovial Sarcoma of the Tibial Nerve: A Case of Diagnostic Ambiguity and Limb Salvage
    • A scientist wearing blue gloves adjusts a microscope slide.
      Can We Reactivate T Cells After TCR-T Therapy Stops Working?
    • Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
      Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    Tags

    #AYACancer #CancerResearch #CaseReport #CellTherapy #ClinicalTrials #Immunotherapy #KnowYourOptions #MAGEA4 #MolecularDiagnostics #NYESO1 #PatientAdvocacy #RareCancer #RareDisease #Sarcoma #SarcomaAwareness #SoftTissueSarcoma #SS18SSX #SynovialSarcoma #SynovialSarcomaFoundation #TumorBoard Afami-cel Afamitresgene autoleucel Cancer Research CHOP immunotherapy MAGE-A4 synovial sarcoma NY-ESO-1 synovial sarcoma precision medicine Rare Cancer rare cancer research rare soft tissue sarcoma research sarcoma research sarcoma treatment soft tissue sarcoma Synovial Sarcoma synovial sarcoma biomarker testing synovial sarcoma diagnosis Synovial Sarcoma Foundation synovial sarcoma immunotherapy synovial sarcoma treatment T-Cell Therapy targeted therapy TCR Therapy TECELRA

    Related posts

    A scientist wearing blue gloves adjusts a microscope slide.
    Clinical Trial, Development

    Can We Reactivate T Cells After TCR-T Therapy Stops Working?

    November 3, 2026 ayushis Comments Off on Can We Reactivate T Cells After TCR-T Therapy Stops Working?

    A new pilot trial at Northwestern University is asking one of the most important questions in synovial sarcoma treatment: when TCR-T therapy stops working, are the T cells truly gone, or can they be brought back to life? Background: The Promise and the Limit of TCR-T Therapy TCR-T cell therapy represents a major advance for […]

    Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
    Latest News, Synovial Sarcoma Registry

    Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    October 28, 2026 ayushis Comments Off on Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    A new study in Advanced Science (October 12, 2026) shows what becomes possible when patients donate tumor tissue and researchers pair it with detailed clinical and genetic data. The same idea drives the Synovial Sarcoma Registry and Biorepository, and every patient who joins makes the next study possible. What the study found Over ten years, […]

    Close-up of blue gloved hands adjusting a microscope with two visible objective lenses, focusing on a glass slide in a laboratory setting.
    Education, Research

    The Cells Around the Tumor May Hold the Key to Improving Immunotherapy in Synovial Sarcoma

    September 14, 2026 ayushis Comments Off on The Cells Around the Tumor May Hold the Key to Improving Immunotherapy in Synovial Sarcoma

    A new study published in PLOS One by Ji-Yong Sung, Jin-Hong Kim, and Yi-Jun Kim from Seoul National University and Ewha Womans University, South Korea, examines a type of cell found in the tissue surrounding tumors, called cancer-associated fibroblasts (CAFs), and asks whether they can predict how a sarcoma patient will respond to immunotherapy. What […]

    The Synovial Sarcoma Foundation is a registered 501(c)(3) nonprofit organization. Tax ID number is 33-4027591. Contributions to the Synovial Sarcoma Foundation are tax-deductible to the extent permitted by law.

    • Terms & conditions
    • Privacy policy
    synovial sarcoma foundation
    • community@synovialsarcoma.org
    1025 Thomas Jefferson St. NW, Suite W-3200, Washington DC 20007
    Facebook-f X-twitter Linkedin

    Navigation

    • About
    • Research Programs
    • Patient Stories
    • Resources

    Stay in touch